In conclusion, our study employed the 3D drug testing system (MDT on chip) and RNA-seq to link sorafenib resistance in HCC to β-catenin activation, suggesting these patients may belong to the CTNNB1 subtype. Here, CTNNB1 is linked to hepatocellular carcinoma.